The Dutch ICU Fighter
May 1, 2020
Life Science Business introduces the Dutch ICU Fighter, the world’s first patented system to relieve the ICU staff of the Prone & Supine positioning of COVID-19 patients.
By using the Dutch ICU Fighter, patients can be turned within 5 minutes with the help of only 2 healthcare professionals. Deploying this system ensures that hospitals save time, fewer staff is necessary and less healthcare costs. In addition, it ensures that less physical effort is required from the hospital staff.
The intention is to deliver the Dutch ICU Fighter to the American and European hospitals on a NON-PROFIT basis during the COVID-19 crisis.
February 19, 2020
Our American and Dutch researchers have invented the revolutionary Dutch Bio-electronic Neurodegenerative Filter Technology (patent application 2019).
DBNF is the first technology and system that is able to filter and block involuntary impulses (such as the Parkinson tremor) sent from the brain to the muscles in arms and/or legs, while allowing the passage of normal voluntary signals of muscle movement without brain surgery.
The advantages of DBNF technology are 70% reduction of the surgery & care costs, no surgery of the central nervous system (brain or spine) is performed, less radical and burdensome surgery, can be performed as an outpatient surgery and with much fewer risks (no chance of blurry vision, slurred speech or other brain complications) and will improve the Quality of Life for (Parkinson) patients with movement disorders.
DBNF is also a 24-hour/365-day tremor monitoring & registration system of every impulse that is sent from the brain to the arms and legs. This data can be used by scientists to develop even better treatment techniques.
The revolutionary Bio-electronic Neurodegenerative Filter Technology DNF can be used for patients with Neuropathic Pain (nerve pain), without surgery in the spinal cord.
Besides Parkinson’s disease Neuropathic Pain is also a progressive neurodegenerative disease and is characterised by a disturbed signal transfer between muscles, nerves and brain cells. Patients with Neuropathic Pain have a persistent sensation of pain, although there is no external stimulation (such as pressure or temperature).
In order to block these unwanted pain signals the (nano) electrodes of the DNF system will be implanted in or on the sensory nerves, which are responsible for the pain signals. Blocking these signals will improve the Quality of Life of these patients enormously.
Life Science Business has filed a patent application (March, 2020) for unique nano electrodes that are capable to register and filter the involuntary signals / impulses from motor or sensory nerves of the peripheral nervous system.
In combination with an electronic (filter) device or an artificial nerve the unwanted signals send from the brain or pain signals send to the brain are recognized and filtered. These nano electrodes will be implanted in or on the nerves by a special DNF surgical technique developed by Dr. Ajay Seth (CSO of Life Science Business).
Our partner in China,
Aeonmed has three R&D centers in Beijing, Shanghai as well as in Pennsylvania, USA. It also has branch companies in Germany and Indonesia. Innovation is always the corporate core competence of the company. By the end of 2016, Aeonmed had totally applied 1158 patents, among which are 747 invention patents. More than 30% of company employees are in R&D department. More than 10% of total sales income is invested into R&D every year.
Monitoring of the vascular stiffness with our Vascular check 1,
“Arterial stiffness is a major risk factor for morbidity and mortality. Although stiffening of the vasculature is a physiological process which occurs during aging, there are many factors resulting in accelerated stiffening. Some conditions, such as aging, cannot be helped; others, however, can be influenced by lifestyle or diet. With the help of new technology and applied scientific research many patients can be monitored and treated after a diagnosed cardiovascular problem”.
Thrombosis Elastic Stocking,
Life Science Business is developing biomaterials improving the effect of elastic stockings by local transdermal application of natural thrombosis-preventing compounds. This novel approach is specifically aimed for use by consumers at elevated risk for temporarily deep vein thrombosis, such as long-distance travellers who have other risk factors for thrombosis (Factor VLeiden, use of oral contraceptives, etc.).
Life Science Business
Flight Forum 40
5657 DB Eindhoven
Tel.: 0031-(0)40-798 3036
Office The Middle East :
Life Science Business
P. O. Box: 122022